| Fisher Family Medicine, Ps | |
|
1020 Anderson Dr Ste 203 Aberdeen WA 98520-1055 | |
| (360) 533-6063 | |
| Not Available |
| Full Name | Fisher Family Medicine, Ps |
|---|---|
| Speciality | Clinic/Center |
| Location | 1020 Anderson Dr Ste 203, Aberdeen, Washington |
| Authorized Official Name and Position | Vanessa Farinas Fisher (FAMILY NURSE PRACTITIONER) |
| Authorized Official Contact | 9073829000 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Fisher Family Medicine, Ps 1290 Se Phillips Rd Unit 203 Shelton WA 98584-7614 Ph: (907) 382-9000 | Fisher Family Medicine, Ps 1020 Anderson Dr Ste 203 Aberdeen WA 98520-1055 Ph: (360) 533-6063 |
| NPI Number | 1679229223 |
|---|---|
| Provider Enumeration Date | 02/22/2022 |
| Last Update Date | 02/22/2022 |
| Medicare PECOS PAC ID | 3870970601 |
|---|---|
| Medicare Enrollment ID | O20220517003130 |
News Archive
"The world is facing two immediate health crises concerning drugs and vaccines: affordable and reliable access to life-sparing medicines and the safety and reliability of those medicines," Laurie Garrett, senior fellow for global health at the Council on Foreign Relations (CFR), writes in the council's Policy Innovation Memorandum No. 21, titled, "Ensuring the Safety and Integrity of the World's Drug, Vaccine, and Medicines Supply."
Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing an implantable microfluid system that can efficiently and durably stabilize intraocular pressure.
Cordis Corporation ("Cordis") announced today that it has reached an agreement with Boston Scientific ("Boston") resolving its Palmaz infringement suit relating to Boston's NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.
Today, SEIU President Mary Kay Henry released the following statement in support of Hillary Clinton's plan to address the care economy vital for America's seniors and people with disabilities.
Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679229223 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Secondary |
| Provider Name | Vanessa F Fisher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215546494 PECOS PAC ID: 8729405402 Enrollment ID: I20200826000969 |
News Archive
"The world is facing two immediate health crises concerning drugs and vaccines: affordable and reliable access to life-sparing medicines and the safety and reliability of those medicines," Laurie Garrett, senior fellow for global health at the Council on Foreign Relations (CFR), writes in the council's Policy Innovation Memorandum No. 21, titled, "Ensuring the Safety and Integrity of the World's Drug, Vaccine, and Medicines Supply."
Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing an implantable microfluid system that can efficiently and durably stabilize intraocular pressure.
Cordis Corporation ("Cordis") announced today that it has reached an agreement with Boston Scientific ("Boston") resolving its Palmaz infringement suit relating to Boston's NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.
Today, SEIU President Mary Kay Henry released the following statement in support of Hillary Clinton's plan to address the care economy vital for America's seniors and people with disabilities.
Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.
› Verified 6 days ago
News Archive
"The world is facing two immediate health crises concerning drugs and vaccines: affordable and reliable access to life-sparing medicines and the safety and reliability of those medicines," Laurie Garrett, senior fellow for global health at the Council on Foreign Relations (CFR), writes in the council's Policy Innovation Memorandum No. 21, titled, "Ensuring the Safety and Integrity of the World's Drug, Vaccine, and Medicines Supply."
Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing an implantable microfluid system that can efficiently and durably stabilize intraocular pressure.
Cordis Corporation ("Cordis") announced today that it has reached an agreement with Boston Scientific ("Boston") resolving its Palmaz infringement suit relating to Boston's NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.
Today, SEIU President Mary Kay Henry released the following statement in support of Hillary Clinton's plan to address the care economy vital for America's seniors and people with disabilities.
Celgene Corporation announced non-GAAP net income of $323.3 million, or non-GAAP diluted earnings per share of $0.69 for the quarter ended June 30, 2010. Non-GAAP net income for the second quarter of 2009 was $216.0 million or non-GAAP diluted earnings per share of $0.46.
› Verified 6 days ago
Timothy H. Troeh, M D P S Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 205 9th Ave, Aberdeen, WA 98520 Phone: 360-589-6982 | |
Hany G Bashandy Md Ps Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1020 Anderson Dr Ste 205, Aberdeen, WA 98520 Phone: 360-533-6038 Fax: 360-538-0807 | |
Kenneth I Hunt Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1006 N H St, Aberdeen, WA 98520 Phone: 360-537-6391 Fax: 360-537-6322 | |
Colette M Kato Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1220 Basich Blvd, Suite A, Aberdeen, WA 98520 Phone: 360-532-1800 Fax: 360-532-2658 | |
Harbor Infectious Diseases Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1730 Graves Ave, Aberdeen, WA 98520 Phone: 360-532-2311 | |
Grays Harbor Vision Clinic, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 301 N Broadway St, Aberdeen, WA 98520 Phone: 360-533-1880 Fax: 360-533-1886 | |
Coastal Internal Medicine, Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1921 Sumner Avenue, Aberdeen, WA 98520 Phone: 360-538-0135 Fax: 360-533-3475 |